natgillin/translations-raw huggingface dataset:
The mean maximum plasma anti-Xa activity level is observed 3 to 5 hours after subcutaneous injection and achieves approximately 0.2, 0.4, 1.0 and 1.3 anti-Xa IU/mL following single subcutaneous administration of 2,000 IU, 4,000 IU, 100 IU/kg and 150 IU/kg (20 mg, 40 mg, 1 mg/kg and 1.5 mg/kg) doses, respectively.
Povprečna največja aktivnost anti-Xa v plazmi se pojavi od 3 do 5 ur po subkutanem injiciranju in doseže po enkratni subkutani uporabi 2.000 i.e. (20 mg) približno 0,2 anti-Xa i.e./ml, po 4.000 i.e. (40 mg) približno 0,4 anti-Xa i.e./ml, po 100 i.e./kg (1 mg/kg) približno 1,0 anti-Xa i.e./ml in po 150 i.e./kg (1,5 mg/kg) približno 1,3 anti-Xa i.e./ml.
Inhixa 15,000 IU (150 mg)/1 mL is 1 mL of solution in: - a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a dark blue polypropylene plunger rod.
15.000 i.e (150 mg)/1 ml je 1 ml raztopine v: injekcijski brizgi iz prozornega, brezbarvnega, nevtralnega stekla tipa I, opremljeni z injekcijsko iglo in ščitnikom igle, z gumijasto zaporko iz klorobutila in s temno modrim polipropilenskim batom.
One pre-filled syringe (0.8 mL) contains 12,000 IU (120 mg) enoxaparin sodium.
Ena napolnjena injekcijska brizga (0,8 ml) vsebuje 12.000 i.e. (120 mg) natrijevega enoksaparinata.
Diluted medicinal product with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose 8 hours
Zdravilo, razredčeno z raztopino natrijevega klorida 9 mg/ml (0,9%) za injiciranje ali 5 % glukozo 8 ur
CARTON (Packs of 1, 2, 6, 10, 20, 50 or 90)
ŠKATLA (pakiranja po 1, 2, 6, 10, 20, 50 ali 90)
Instructions on injecting yourself with Inhixa
NAVODILA ZA UPORABO: NAPOLNJENA INJEKCIJSKA BRIZGA Kako si injicirate zdravilo Inhixa
- Changing from blood thinners called vitamin-K antagonists (e.g. warfarin) to Inhixa Stop taking the vitamin-K antagonist.
- Prehod s sredstev za redčenje krvi, imenovanih antagonisti vitamina K (npr. varfarin) na zdravilo Inhixa
Enoxaparin sodium, as with any other anticoagulant therapy, should be used with caution in conditions with increased potential for bleeding, such as: - impaired haemostasis, - history of peptic ulcer, - recent ischemic stroke, - severe arterial hypertension, - recent diabetic retinopathy, - neuro- or ophthalmologic surgery, - concomitant use of medicinal products affecting haemostasis (see section 4.5).
Tako kot druge antikoagulanse je treba tudi natrijev enoksaparinat previdno uporabljati pri stanjih, povezanih z večjo možnostjo za krvavitve; takšna so npr.: - okvarjena hemostaza, - anamneza peptične razjede, - nedavna ishemična možganska kap, - huda arterijska hipertenzija, - nedavna diabetična retinopatija, - nevrološka ali oftalmološka operacija, - sočasna uporaba zdravil, ki poslabšajo hemostazo (glejte poglavje 4.5).
- Changing from Inhixa to treatment with direct oral anticoagulant Stop taking Inhixa.
- Prehod z zdravila Inhixa na zdravljenje z neposrednim peroralnim antikoagulansom Nehajte jemati zdravilo Inhixa.
Switch between enoxaparin sodium and direct oral anticoagulants (DOAC) For patients currently receiving enoxaparin sodium, discontinue enoxaparin sodium and start the DOAC 0 to 2 hours before the time that the next scheduled administration of enoxaparin sodium would be due as per DOAC label.
Bolnikom, ki trenutno prejemajo natrijev enoksaparinat, slednjega ukinite in uvedite DOAC od 0 do 2 uri pred časom, ko bi bil na vrsti naslednji redni odmerek natrijevega enoksaparinata (v skladu z navodili za uporabo DOAC).
Each pre-filled syringe contains enoxaparin sodium 15,000 IU anti-Xa activity (equivalent to 150 mg) in 1 mL water for injections.
Ena napolnjena injekcijska brizga vsebuje 15.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 150 mg) v 1 ml vode za injekcije.
Enoxaparin sodium 2,000 IU (20 mg) once a day subcutaneously n (%)
Natrijev enoksaparinat 2.000 i.e. (20 mg) enkrat na dan subkutano n (%)
Intracranial haemorrhage, Retroperitoneal haemorrhage α: such as haematoma, ecchymosis other than at injection site, wound haematoma, haematuria, epistaxis and gastro-intestinal haemorrhage.
Intrakranialna krvavitev, retroperitonealna krvavitev : npr. hematom, ekhimoze drugje kot na mestu injiciranja, hematom rane, hematurija, epistaksa in gastrointestinalna krvavitev.
VTE = venous thromboembolic event (DVT and/or PE) *The 95% Confidence Intervals for the treatment differences for total VTE were: - enoxaparin sodium once a day versus heparin (-3.0 to 3.5) - enoxaparin sodium every 12 hours versus heparin (-4.2 to 1.7).
VTE = venski trombembolični dogodek (GVT in/ali PE) *95-odstotna intervala zaupanja za razliko med zdravljenji za vse VTE sta bila: - natrijev enoksaparinat enkrat na dan v primerjavi s heparinom (-3,0 do 3,5) - natrijev enoksaparinat na 12 ur v primerjavi s heparinom (-4,2 do 1,7)
Inhixa 15,000 IU (150 mg)/1 mL solution for injection
Inhixa 15.000 i.e. (150 mg)/1 ml raztopina za injiciranje
Inhixa 100,000 IU (1000 mg)/10 mL solution for injection in multidose vial
Inhixa 100.000 i.e. (1000 mg)/10 ml raztopina za injiciranje v večodmerni viali
The air bubble should not be expelled from the syringe before the injection to avoid the loss of drug when using pre-filled syringes.
V primeru uporabe napolnjene injekcijske brizge iz nje pred injiciranjem ni priporočljivo odstraniti zračnega mehurčka, da ne pride do izgube zdravila.
SC injection Do not mix with other products.
Subkutano injiciranje Zdravila Inhixa ne smete mešati z drugimi zdravili.
Enoxaparin sodium, as with any other anticoagulant therapy, should be used with caution in conditions with increased potential for bleeding, such as: - impaired haemostasis, - history of peptic ulcer, - recent ischemic stroke, - severe arterial hypertension, recent diabetic retinopathy, - neuro- or ophthalmologic surgery, - concomitant use of medications affecting haemostasis (see section 4.5).
Tako kot druge antikoagulanse je treba tudi natrijev enoksaparinat previdno uporabljati pri stanjih, povezanih z večjo možnostjo za krvavitve; takšna so npr.: - okvarjena hemostaza, - anamneza peptične razjede, - nedavna ishemična možganska kap, - huda arterijska hipertenzija, - nedavna diabetična retinopatija, nevrološka ali oftalmološka operacija, - sočasna uporaba zdravil, ki poslabšajo hemostazo (glejte poglavje 4.5).
One vial contains enoxaparin sodium 30,000 IU anti-Xa activity (equivalent to 300 mg) in 3.0 mL water for injections.
Ena viala vsebuje 30.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 300 mg) v 3,0 ml vode za injekcije.
Volume to inject when diluted to a final concentration of 300 IU (3 mg)/mL
Količina, ki jo je treba injicirati, če je razredčenje opravljeno na končno koncentracijo 300 i.e. (3 mg) / ml
Common: Thrombocytopenia
Pogosti: Trombocitozaβ
One pre-filled syringe (1 mL) contains 15,000 IU (150 mg) enoxaparin sodium
Ena napolnjena injekcijska brizga (1 ml) vsebuje 15.000 i.e. (150 mg) natrijevega enoksaparinata
Treatment of acute ST-segment elevation myocardial infarction In a large multicentre study, 20,479 patients with STEMI eligible to receive fibrinolytic therapy were randomized to receive either enoxaparin sodium in a single 3,000 IU (30 mg) intravenous bolus plus a 100 IU/kg (1 mg/kg) subcutaneous dose followed by an subcutaneous injection of 100 IU/kg (1 mg/kg) every 12 hours or intravenous unfractionated heparin adjusted based on aPTT for 48 hours.
Zdravljenje akutnega miokardnega infarkta z dvigom spojnice ST V veliki multicentrični študiji so 20.479 bolnikov s STEMI, primernih za fibrinolitično zdravljenje, za 48 ur randomizirali ali na natrijev enoksaparinat v enkratnem intravenskem bolusu 3.000 i.e. (30 mg) ter 100 i.e./kg (1 mg/kg) subkutano, čemur je sledilo subkutano injiciranje 100 i.e./kg (1 mg/kg) na 12 ur ali na nefrakcionirani heparin intravensko glede na aPTČ.
One vial contains enoxaparin sodium 100,000 IU anti-Xa activity (equivalent to 1000 mg) in 10.0 mL water for injections.
Ena viala vsebuje 100.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 1000 mg) v 10,0 ml vode za injekcije.
Inhixa each day.
Inhixa na dan.
One vial (10.0 mL) contains 100,000 IU (1000 mg) enoxaparin sodium.
Ena viala (10,0 ml) vsebuje 100.000 i.e. (1000 mg) natrijevega enoksaparinata.
Pharmacotherapeutic group: Antithrombotic agents, heparin group.
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: antitrombotiki, heparinska skupina, oznaka ATC: B01A B05
Inhixa 4,000 IU (40 mg)/0.4 mL is 0.4 mL of solution in: - a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a yellow polypropylene plunger rod.
Inhixa 4.000 i.e. (40 mg)/0,4 mL je 0,4 ml raztopine v: injekcijski brizgi iz prozornega, brezbarvnega, nevtralnega stekla tipa I, opremljeni z injekcijsko iglo in ščitnikom igle, z gumijasto zaporko iz klorobutila in z modrim polipropilenskim batom.
Very common: Thrombocytosi s β
Zelo pogosti: Trombocitoza β
In a second double-blind study, 262 patients without VTE disease and undergoing hip replacement surgery initially treated, while hospitalized, with enoxaparin sodium 4,000 IU (40 mg) subcutaneously were randomized to a post-discharge regimen of either enoxaparin sodium 4,000 IU (40 mg) (n=131) once a day subcutaneously or to placebo (n=131) for 3 weeks.
V drugi dvojno slepi študiji so 262 bolnikov brez venske trombembolične bolezni in z operativno zamenjavo kolka, ki so bili med hospitalizacijo uvodoma zdravljeni z natrijevim enoksaparinatom 4.000 i.e. (40 mg) subkutano, po odpustu za 3 tedne randomizirali na shemo z natrijevim enoksaparinatom 4.000 i.e. (40 mg) subkutano enkrat na dan (n = 131) ali na placebo (n = 131).
Subcutaneous injection technique
Postopek subkutanega injiciranja
One vial (3.0 mL) contains 30,000 IU (300 mg) enoxaparin sodium.
Ena viala (3,0 ml) vsebuje 30.000 i.e.e (300 mg) natrijevega enoksaparinata.
Enoxaparin sodium 4,000 IU (40 mg) once a day subcutaneously n (%)
Natrijev enoksaparinat 4.000 i.e. (40 mg) enkrat na dan subkutano n (%)
The following medicinal products may be administered with caution concomitantly with enoxaparin sodium: Other medicinal products affecting haemostasis such as: - Platelet aggregation inhibitors including acetylsalicylic acid used at antiaggregant dose (cardioprotection), clopidogrel, ticlopidine, and glycoprotein IIb/IIIa antagonists indicated in acute coronary syndrome due to the risk of bleeding, - Dextran 40, - Systemic glucocorticoids.
Naslednja zdravila se lahko previdno uporabijo sočasno z natrijevim enoksaparinatom: Druga zdravila, ki vplivajo na hemostazo, na primer: - zaviralci agregacije trombocitov, vključno z acetilsalicilno kislino v antiagregacijskih odmerkih (zaščita srca), klopidogrel, tiklopidin in antagonisti glikoproteina IIb/IIIa, ki so indicirani pri akutnem koronarnem sindromu, zaradi tveganja za krvavitve, - dekstran 40, - sistemski glukokortikoidi.
Switch between enoxaparin sodium and oral anticoagulants Switch between enoxaparin sodium and vitamin K antagonists (VKA) Clinical monitoring and laboratory tests [prothrombin time expressed as the International Normalized Ratio (INR)] must be intensified to monitor the effect of VKA.
Prehod med natrijevim enoksaparinatom in peroralnimi antikoagulansi Prehod med natrijevim enoksaparinatom in antagonisti vitamina K (VKA - Vitamin K Antagonists) Za nadzor nad učinkom VKA je treba poostriti klinični nadzor in laboratorijske preiskave (protrombinski čas, izražen kot internacionalno normalizirano razmerje [INR]).
The syringe can be additionally equipped with needle guard; or - a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a white polycarbonate plunger rod equipped with UltraSafe Passive needle guard.
Injekcijske brizge so lahko dodatno opremljene z napravo za preprečevanje vboda po injiciranju; ali graduirani injekcijski brizgi iz prozornega, brezbarvnega, nevtralnega stekla tipa I, opremljeni z injekcijsko iglo in ščitnikom igle, z gumijasto zaporko iz klorobutila in z belym polikarbonatskim batom.
The syringe can be additionally equipped with needle guard; or - a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a white polycarbonate plunger rod equipped with UltraSafe Passive needle guard.
Injekcijske brizge so lahko dodatno opremljene z napravo za preprečevanje vboda po injiciranju; ali injekcijski brizgi iz prozornega, brezbarvnega, nevtralnega stekla tipa I, opremljeni z injekcijsko iglo in ščitnikom igle, z gumijasto zaporko iz klorobutila in z belym polikarbonatskim batom.
• DVT Only (%)
Samo GVT (%)
Inhixa 15,000 IU (150 mg)/1 mL solution for injection enoxaparin sodium
Inhixa 15.000 i.e. (150 mg)/1 ml raztopina za injiciranje natrijev enoksaparinat
What Inhixa looks like and contents of the pack - 3 mL of solution in clear, colourless type I glass vial sealed with rubber injection stopper and white aluminium-plastic cap in a cardboard box.
Izgled zdravila Inhixa in vsebina pakiranja 3 ml raztopine v viali iz prozornega, brezbarvnegastekla tipa I, zatesnjena z gumijasto zaporko za iglo in belim aluminijstoplastičnim pokrovčkom v kartonski škatli.
CARTON OF (Packs of 2, 5, 6, 10, 20, 30, 50 or 90)
ŠKATLA PO (pakiranja po 2, 5, 6, 10, 20, 30, 50 ali 90)
Inhixa 10,000 IU (100 mg)/1 mL solution for injection
Inhixa 10.000 i.e. (100 mg)/1 ml raztopina za injiciranje
Inhixa 30,000 IU (300 mg)/3 mL solution for injection in multidose vial enoxaparin sodium
Inhixa 30.000 i.e. (300 mg)/3 ml raztopina za injiciranje v večodmerni viali natrijev enoksaparinat
Hold the syringe in the hand you write with (like a pencil) and with your other hand, gently pinch the cleaned area of your abdomen between your forefinger and thumb to make a fold in the skin
Z drugo roko nežno stisnite očiščeni del kože na trebuhu med palec in kazalec, da bo nastala kožna guba.
One vial (3 mL) contains 30,000 IU (300 mg) enoxaparin sodium.
Ena viala (3 ml) vsebuje 30.000 i.e. (300 mg) natrijevega enoksaparinata.
One vial (10 mL) contains 100,000 IU (1000 mg) enoxaparin sodium.
Ena viala (10 ml) vsebuje 100.000 i.e. (1000 mg) natrijevega enoksaparinata.
CARTON OF (Packs of 2, 6, 10, 12, 24, 30, 50 or 90)
ŠKATLA PO (pakiranja po 2, 6, 10, 12, 24, 30, 50 ali 90)
Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection
Inhixa 4.000 i.e. (40 mg)/ 0,4 ml raztopina za injiciranje
• you are going to receive spinal or epidural anesthesia or lumbar puncture (see Operations and
• če boste prejeli spinalno ali epiduralno anestezijo ali lumbalno punkcijo (glejte Operacije in anestezija): upoštevati je treba zakasnitev med uporabo zdravila Inhixa in tem postopkom.
Prevention of venous thromboembolic disease associated with surgery Extended prophylaxis of VTE following orthopaedic surgery In a double blind study of extended prophylaxis for patients undergoing hip replacement surgery, 179 patients with no venous thromboembolic disease initially treated, while hospitalized, with enoxaparin sodium 4,000 IU (40 mg) subcutaneously, were randomized to a post-discharge regimen of either enoxaparin sodium 4,000 IU (40 mg) (n=90) once a day subcutaneously or to placebo (n=89) for 3 weeks.
Preprečevanje venske tromboembolične bolezni, povezane z operacijami Podaljšana profilaksa VTE po ortopedskih operacijah V dvojno slepi študiji podaljšane profilakse pri bolnikih z operativno zamenjavo kolka so 179 bolnikov brez venske trombembolične bolezni, ki so bili med hospitalizacijo uvodoma zdravljeni z natrijevim enoksaparinatom 4.000 i.e. (40 mg) subkutano, po odpustu za 3 tedne randomizirali na shemo z natrijevim enoksaparinatom 4.000 i.e. (40 mg) subkutano enkrat na dan (n = 90) ali na placebo (n = 89).
Each pre-filled syringe contains enoxaparin sodium 4,000 IU anti-Xa activity (equivalent to 40 mg) in 0.4 mL water for injections.
Ena napolnjena injekcijska brizga vsebuje 4.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 40 mg) v 0,4 ml vode za injekcije.
Multiple dose vials containing benzyl alcohol:
6.1 Seznam pomožnih snovi Benzilalkohol
Inhixa 50,000 IU (500 mg)/5 mL solution for injection in multidose vial enoxaparin sodium
Inhixa 50.000 i.e. (500 mg)/5 ml raztopina za injiciranje v večodmerni viali natrijev enoksaparinat
Immunoallergic thrombocytope nia
Imunoalergijska trombocitopeni ja
Each pre-filled syringe contains enoxaparin sodium 12,000 IU anti-Xa activity (equivalent to 120 mg) in 0.8 mL water for injections.
Ena napolnjena injekcijska brizga vsebuje 12.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 120 mg) v 0,8 ml vode za injekcije.
Each pre-filled syringe contains enoxaparin sodium 6,000 IU anti-Xa activity (equivalent to 60 mg) in 0.6 mL water for injections.
Ena napolnjena injekcijska brizga vsebuje 6.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 60 mg) v 0,6 ml vode za injekcije.
Inhixa 6,000 IU (60 mg)/0.6 mL solution for injection
Inhixa 6.000 i.e. (60 mg)/ 0,6 ml raztopina za injiciranje
Skin necrosis / cutaneous vasculitis
Nekroza kože/kožni vaskulitis
The syringe can be additionally equipped with needle guard; or
Injekcijske brizge so lahko dodatno opremljene z napravo za preprečevanje vboda po injiciranju;
Illness
Dojenje
Inhixa 8,000 IU (80 mg)/0.8 mL solution for injection
Inhixa 8.000 i.e. (80 mg)/0,8 ml raztopina za injiciranje
10,000 IU/mL (100 mg/mL) solution for injection
KAKOVOSTNA IN KOLIČINSKA SESTAVA 10.000 i.e./ml (100 mg/ml) raztopina za injiciranje
Inhixa 8,000 IU (80 mg)/0.8 mL is 0.8 mL of solution in: - a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a red polypropylene plunger rod.
Inhixa 8.000 i.e. (80 mg)/0,8 mL je 0,8 ml raztopine v: injekcijski brizgi iz prozornega, brezbarvnega, nevtralnega stekla tipa I, opremljeni z injekcijsko iglo in ščitnikom igle, z gumijasto zaporko iz klorobutila in z modrim polipropilenskim batom.
Inhixa 2,000 IU (20 mg)/0.2 mL solution for injection
Inhixa 2.000 i.e. (20 mg)/ 0,2 ml raztopina za injiciranje
Each pre-filled syringe contains enoxaparin sodium 8,000 IU anti-Xa activity (equivalent to 80 mg) in 0.8 mL water for injections.
Ena napolnjena injekcijska brizga vsebuje 8.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 80 mg) v 0,8 ml vode za injekcije.
CARTON OF (Packs of 2, 6, 10, 12, 20, 24 or 30)
ŠKATLA PO (pakiranja po 2, 6, 10, 12, 20, 24 ali 30)
Each mL contains 10,000 IU (100 mg) enoxaparin sodium.
En ml vsebuje 10.000 i.e. (100 mg) natrijevega enoksaparina.
Inhixa 12,000 IU (120 mg)/0.8 mL solution for injection
Inhixa 12.000 i.e. (120 mg)/0,8 ml raztopina za injiciranje
Treatment of unstable angina and non ST elevation myocardial infarction In a large multicentre study, 3,171 patients enrolled at the acute phase of unstable angina or non-Q-wave myocardial infarction were randomized to receive in association with acetylsalicylic acid (100 to 325 mg once daily), either subcutaneous enoxaparin sodium 100 IU/kg (1 mg/kg) every 12 hours or intravenous unfractionated heparin adjusted based on aPTT.
Zdravljenje nestabilne angine pektoris in miokardnega infarkta brez dviga spojnice ST V veliki multicentrični študiji so 3.171 bolnikov, vključenih v akutni fazi nestabilne angine pektoris ali miokardnega infarkta brez zobca Q, randomizirali na prejemanje natrijevega enoksaparinata 100 i.e./kg (1 mg/kg) subkutano na 12 ur ali nefrakcioniranega heparina intravensko s prilagoditvijo glede na aPTČ.
Inhixa 100,000 IU (1000 mg)/10 mL solution for injection in multidose vial enoxaparin sodium
Inhixa 100.000 i.e. (1000 mg)/10 ml raztopina za injiciranje v večodmerni viali natrijev enoksaparinat
Switch between enoxaparin sodium and vitamin K antagonists (VKA) Clinical monitoring and laboratory tests [prothrombin time expressed as the International Normalized Ratio (INR)] must be intensified to monitor the effect of VKA.
Prehod med natrijevim enoksaparinatom in antagonisti vitamina K (VKA - Vitamin K Antagonists) Za nadzor nad učinkom VKA je treba poostriti klinični nadzor in laboratorijske preiskave (protrombinski čas, izražen kot internacionalno normalizirano razmerje [INR]).
Enoxaparin sodium may be safely administered with sodium chloride 9 mg/ml (0.9%) solution for infusion or 5% glucose solution for injection (see section 4.2).
Natrijev enoksaparinat lahko varno dajemo z raztopino natrijevega klorida 9 mg/ml (0,9 %) za infundiranje ali 5 % raztopino glukoze za injiciranje (glejte poglavje 4.2).
1 mL of solution in a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a dark blue polypropylene plunger rod.
1 ml raztopine v injekcijski brizgi iz prozornega, brezbarvnega, nevtralnega stekla tipa I, opremljeni z injekcijsko iglo in ščitnikom igle, z gumijasto zaporko iz klorobutila in s temno modrim polipropilenskim batom.
Each pre-filled syringe contains enoxaparin sodium 2,000 IU anti-Xa activity (equivalent to 20 mg) in 0.2 mL water for injections.
Ena napolnjena injekcijska brizga vsebuje 2.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 20 mg) v 0,2 ml vode za injekcije.
Inhixa 4,000 IU (40 mg) /0.4 mL injection enoxaparin sodium
Inhixa 4.000 i.e. (40 mg)/0,4 ml raztopina za injiciranje enoksaparin
CARTON OF (Packs of 2, 6, 10, 12, 24 or 30)
ŠKATLA PO (pakiranja po 2, 6, 10, 12, 24 ali 30)
Inhixa 12,000 IU (120 mg)/0.8 mL injection enoxaparin sodium
Inhixa 12.000 i.e. (120 mg)/0,8 ml raztopina za injiciranje natrijev enoksaparinat
How to store Inhixa
Kako si injicirate zdravilo Inhixa
Inhixa 8,000 IU (80 mg)/0.8 mL injection enoxaparin sodium
Inhixa 8.000 i.e. (80 mg)/0,8 ml raztopina za injiciranje enoksaparin
Inhixa 6,000 IU (60 mg)/0.6 mL is 0.6 mL of solution in: - a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and an orange polypropylene plunger rod.
Inhixa 6.000 i.e. (60 mg)/0,6 mL je 0,6 ml raztopine v: injekcijski brizgi iz prozornega, brezbarvnega, nevtralnega stekla tipa I, opremljeni z injekcijsko iglo in ščitnikom igle, z gumijasto zaporko iz klorobutila in z modrim polipropilenskim batom.
After dilution with sodium chloride 9 mg/ml (0.9%) solution for infusion or 5% glucose solution for injection
Po razredčitvi z raztopino natrijevega klorida 9 mg/ml (0,9 %) za infundiranje ali 5% raztopino glukoze za injiciranje
Packs of: - 2, 10 and 30 pre-filled syringes, - 10 and 30 pre-filled syringes with a needle guard.
Pakiranje po: - 2, 10 in 30 napolnjenih injekcijskih brizg - 10 in 30 napolnjenih injekcijskih brizg s pripomočkom za zaščito igle
Inhixa 6,000 IU (60 mg)/0.6 mL injection enoxaparin sodium
Inhixa 6.000 i.e. (60 mg)/0,6 ml raztopina za injiciranje enoksaparin
Enoxaparin sodium may be safely administered with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% dextrose in water (see section 4.2).
Natrijev enoksparinat lahko varno daste z raztopino natrijevega klorida 9 mg/ml (0,9 %) za injekcije ali 5 % glukozo v vodi (glejte poglavje 4.2).
Supplied in packs of: - 2, 10 and 30 pre-filled syringes, - 10 and 30 pre-filled syringes with needle guard.
Pakirano v škatlah po: - 2, 10 in 30 napolnjenih injekcijskih brizg, - 10 in 30 napolnjenih injekcijskih brizg s pripomočkom za zaščito igle.
Inhixa 2,000 IU (20 mg)/0.2 mL solution for injection enoxaparin sodium
Inhixa 2.000 i.e. (20 mg)/0,2 ml raztopina za injiciranje enoksaparin
To obtain a 300 IU/mL (3 mg/mL) solution, using a 6,000 IU (60 mg) enoxaparin sodium pre-filled syringe, it is recommended to use a 50 mL infusion bag (i.e. using either normal sodium chloride 9 mg/mL (0.9%) solution for infusion or 5% glucose in water for injections) as follows:
Za pripravo raztopine 300 i.e./ml (3 mg/ml) z uporabo napolnjene injekcijske brizge s 6.000 i.e. (60 mg) natrijevega enoksaparinata je priporočljivo uporabiti 50-ml infuzijsko vrečko (tj. z uporabo raztopine natrijevega klorida 9 mg/ml (0,9 % za injekcije ali 5 % raztopine glukoze v vodi) takole: Iz infuzijske vrečke z brizgo je treba odvzeti 30 ml raztopine in jo zavreči.
• you have kidney problems
• če imate težave z ledvicami